Otonomy Appoints Dean Hakanson, M.D., as Chief Medical Officer
April 01 2015 - 7:00AM
Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical
company focused on the development and commercialization of
innovative therapeutics for diseases and disorders of the inner and
middle ear, today announced the appointment of Dean Hakanson, M.D.,
as chief medical officer. Dr. Hakanson has more than 16 years of
industry experience in medical affairs, market access and health
economic research with leading pharmaceutical companies including
Novartis, Bristol-Myers Squibb, Genentech and GlaxoSmithKline.
"Dean's depth of knowledge and experience in medical affairs,
market access, and reimbursement support activities will be
extremely valuable as Otonomy prepares for commercialization of our
first product," said David A. Weber, Ph.D., president and CEO of
Otonomy. "We look forward to working with Dean as we prepare to
launch AuriPro™ in the U.S. market in the first quarter of 2016,
and will also leverage his outcomes research expertise in the
development of our other product candidates."
Dr. Hakanson joins Otonomy from Novartis, where he served as the
vice president and head of health economics & outcomes research
(HE&OR) for U.S. medical and drug regulatory affairs, preceded
by a role as the vice president and medical head of the west
operating unit where he led a field-based medical organization.
Previous to Novartis he served as the vice president of healthcare
access at Bristol-Myers Squibb, and prior to this position he
served as the head of value-based healthcare/payer field team at
Genentech. He also previously held positions of increasing
responsibility at GlaxoSmithKline, most recently serving as vice
president, medical affairs commercial operations; preceded by roles
as vice president of managed markets, national accounts; medical
director, Cigna national account; and director, client and
strategic alliance.
Prior to joining GlaxoSmithKline, Dr. Hakanson was a medical
director and critical care physician at John C. Lincoln IDS in
Phoenix, Ariz. Previous to this role, he was a medical director and
critical care physician at Tenet Healthcare Corporation in San
Francisco, Calif. Currently, Dr. Hakanson is a diplomat of the
American College of Physician Executives and diplomat of the
American Board of Anesthesiology and American Society of
Anesthesiologists. He obtained a medical degree from the University
of Colorado School of Medicine and a bachelor's degree in cellular
physiology and physics from the University of Denver.
About Otonomy
Otonomy is a clinical-stage biopharmaceutical company focused on
the development and commercialization of innovative therapeutics
for diseases and disorders of the ear. Otonomy's proprietary
technology provides sustained exposure of drugs to the middle and
inner ear following a single intratympanic injection. Otonomy has
three product candidates in development. AuriPro™ is an antibiotic
that has completed Phase 3 clinical trials in pediatric patients
with middle ear effusion at the time of tympanostomy tube placement
surgery, and a New Drug Application for AuriPro in this indication
has been submitted to the FDA. OTO-104 is a steroid that is in the
first of two pivotal clinical studies for the treatment of patients
with Ménière's disease. OTO-311 is an NMDA receptor antagonist in
development as a treatment for tinnitus. For additional information
please visit www.otonomy.com.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or Otonomy's future financial or operating performance.
Forward-looking statements in this press release include, but are
not limited to, Otonomy's expectations regarding the commercial
launch of AuriPro™ in the United States and the development of its
other product candidates. Otonomy's expectations regarding these
matters may not materialize, and actual results in future periods
are subject to risks and uncertainties. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of these risks and uncertainties, including but not
limited to: the uncertainties inherent in the clinical drug
development process, including, without limitation, Otonomy's
ability to adequately demonstrate the safety and efficacy of its
product candidates, the preclinical and clinical results for its
product candidates, which may not support further development of
product candidates, and challenges related to patient enrollment in
clinical trials; Otonomy's ability to obtain regulatory approval
for its product candidates; side effects or adverse events
associated with Otonomy's product candidates; developments related
to competitors and the industry; Otonomy's dependence on third
parties to conduct preclinical studies and clinical trials;
Otonomy's dependence on third parties for the manufacture of
products; Otonomy's dependence on a small number of suppliers for
raw materials; Otonomy's ability to protect its intellectual
property related to product candidates in the United States and
throughout the world; and other risks. Information regarding the
foregoing and additional risks may be found in the section entitled
"Risk Factors" in Otonomy's Annual Report on Form 10-K filed with
the Securities and Exchange Commission (the SEC) on March 18, 2015,
and Otonomy's future reports to be filed with the SEC. The
forward-looking statements in this press release are based on
information available to Otonomy as of the date hereof. Otonomy
disclaims any obligation to update any forward-looking statements,
except as required by law.
CONTACT: Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Vice President
619.849.5377
heidi@canalecomm.com
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jul 2023 to Jul 2024